In conversation with...

John Collinge on a treatment for CJD

March 16, 2022 The Lancet Neurology
In conversation with...
John Collinge on a treatment for CJD
Show Notes

John Collinge (MRC Prion Unit, University College London, London, UK) discusses a first-in-human treatment programme to give PRN100, an anti-prion-protein monoclonal antibody, to patients with Creutzfeldt–Jakob disease; the report is published in the April issue of The Lancet Neurology.